The most widely prescribed diabetes drug is being repurposed for longevity. The TAME trial aims to prove metformin targets the root cause of aging.
Last updated: March 2026
Metformin is a first-line medication for type 2 diabetes, prescribed since 1957. It works by activating AMPK (AMP-activated protein kinase) — the cellular energy sensor — and reducing liver glucose production. More recently, it's been studied as a longevity compound due to observational data showing reduced age-related diseases in diabetic patients.
Metformin activates AMPK, the master regulator of cellular energy. This triggers glucose uptake, improves insulin sensitivity, and activates autophagy — cellular cleanup.
Indirectly inhibits mTOR (like rapamycin but through different pathways). Combined AMPK activation + mTOR inhibition is a powerful anti-aging combination.
Targeting Aging with Metformin — the landmark trial designed to prove that metformin treats the root cause of aging, not just symptoms. First "anti-aging" drug trial.
Multiple studies show metformin users have reduced all-cause mortality, cardiovascular disease, cancer, and cognitive decline vs non-diabetics and even non-metformin diabetics.
Key insight: Most data is observational (diabetics on metformin vs those not). The TAME trial will provide RCT evidence. Non-diabetic use is off-label.
• GI upset: Nausea, diarrhea, stomach pain (very common, especially initially)
• B12 deficiency: Long-term use depletes B12 — supplement
• Lactic acidosis: Rare but serious — contraindicated in kidney disease
• Start low: 500mg with dinner, increase slowly
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational purposes only. Metformin is a prescription drug. Off-label use for longevity requires medical supervision. Consult a healthcare provider.